ArticleBlood neoplasia2024

Prospective performance of the IWG-2023 criteria and IPSS-M in a phase 2 trial of guadecitabine for higher-risk MDS or CMML.

Samuel Urrutia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.